Literature DB >> 16806167

Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment.

Michael Didriksen1, Mads Kreilgaard, Jørn Arnt.   

Abstract

Cognitive deficits in schizophrenia are associated with poor functional outcome, and may be further aggravated by treatment with antipsychotics. In the present study the acute and chronic (3 weeks of treatment) effects of clozapine, olanzapine, and sertindole on performance in the Morris water maze in rats was compared, using pharmacologically and/or clinically relevant dose regimens. An experimental design consisting of three trials/day over 3 days was used. Performance was expressed as the distance and latency to find a submerged platform, as well as the percentage of "non-finders", i.e. percentage of trials where the rat was unable to find the platform within the total trial time of 60 s. Clozapine (40 mg/kg, p.o.) and olanzapine (2.5 mg/kg, s.c.) impaired water maze performance when given acutely. However, tolerance developed to the deficit induced by clozapine, whereas the olanzapine-mediated impairment was enhanced after chronic treatment. Sertindole (2.5 mg/kg, p.o.) had no disruptive effect on performance after either acute or chronic treatment. Exposure measurements confirmed that all three compounds were present in the serum at least at clinically effective concentrations. Thus, the three antipsychotics tested differentially affected rodent cognition, whereby sertindole appeared to have a lower potential than either clozapine or olanzapine to induce cognitive impairment. The hypothesis that the low potency of sertindole in inducing dopamine D2 receptor blockade, combined with lack of antimuscarinic and histamine H1 antagonist activity in vivo is discussed. Clearly further studies are needed to assess the potential cognition-enhancing effects of sertindole vs. other antipsychotics in a relevant animal model of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806167     DOI: 10.1016/j.ejphar.2006.05.021

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Differential long-term effects of haloperidol and risperidone on the acquisition and performance of tasks of spatial working and short-term memory and sustained attention in rats.

Authors:  Elizabeth J Hutchings; Jennifer L Waller; Alvin V Terry
Journal:  J Pharmacol Exp Ther       Date:  2013-09-16       Impact factor: 4.030

2.  Sertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPP.

Authors:  Mirjana Carli; Eleonora Calcagno; Ester Mainini; Jorn Arnt; Roberto W Invernizzi
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

3.  Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats.

Authors:  A V Terry; S E Warner; L Vandenhuerk; A Pillai; S P Mahadik; G Zhang; M G Bartlett
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

4.  Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits.

Authors:  Ann N Hoffman; Jeffrey P Cheng; Ross D Zafonte; Anthony E Kline
Journal:  Life Sci       Date:  2008-08-31       Impact factor: 5.037

5.  Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole.

Authors:  Felice Iasevoli; Carmine Tomasetti; Federica Marmo; Daniele Bravi; Jørn Arnt; Andrea de Bartolomeis
Journal:  Psychopharmacology (Berl)       Date:  2010-07-23       Impact factor: 4.530

6.  Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance.

Authors:  A V Terry; D A Gearhart; S E Warner; G Zhang; M G Bartlett; M-L Middlemore; W D Beck; S P Mahadik; J L Waller
Journal:  Neuroscience       Date:  2007-04-16       Impact factor: 3.590

7.  Emerging role of sertindole in the management of schizophrenia.

Authors:  Stephanie L Cincotta; Joshua S Rodefer
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

8.  Cognitive performance in neurokinin 3 receptor knockout mice.

Authors:  R E Nordquist; M Delenclos; T M Ballard; H Savignac; M Pauly-Evers; L Ozmen; W Spooren
Journal:  Psychopharmacology (Berl)       Date:  2008-03-20       Impact factor: 4.530

9.  Clozapine Improves Memory Impairment and Reduces Aβ Level in the Tg-APPswe/PS1dE9 Mouse Model of Alzheimer's Disease.

Authors:  Yura Choi; Ha Jin Jeong; Quan Feng Liu; Seung Tack Oh; Byung-Soo Koo; Yeni Kim; In-Won Chung; Yong Sik Kim; Songhee Jeon
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

Review 10.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.